CD274 and neoplasm: Existing anti-PD1/PDL1 therapy interdicts the combination between PD1 and PDL1, and effectively activates depleted immune cells and triggers an anti-tumor immune response (Ribas et al., 2018; Seidel et al., 2018; Liang et al., 2021).